Compare SHAK & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | VERA |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | 2014 | 2021 |
| Metric | SHAK | VERA |
|---|---|---|
| Price | $63.86 | $33.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 10 |
| Target Price | ★ $117.29 | $81.30 |
| AVG Volume (30 Days) | ★ 2.2M | 928.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,445,306,000.00 | N/A |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $15.07 | $472.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $59.49 | $18.76 |
| 52 Week High | $142.23 | $56.05 |
| Indicator | SHAK | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 34.89 |
| Support Level | N/A | $27.19 |
| Resistance Level | $94.90 | $42.77 |
| Average True Range (ATR) | 3.61 | 2.04 |
| MACD | -2.91 | -0.08 |
| Stochastic Oscillator | 9.75 | 5.93 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.